Arginase-1 is a promising new drug target for cancer immunotherapy. A novel assay technology for high-throughput screening (HTS) of Arginase-1 has been published in SLAS Discovery  by researchers from NTRC in collaboration with Pivot Park Screening Centre (PPSC). The assay technology is known as Arginase Gold™.

NTRC is a precision medicine company dedicated to discovering new anti-cancer drug candidates. It is their mission to help you finding a mechanistic hypothesis before entering the clinic. NIRC provides cell-based profiling services, target residence time measurements, biochemical profiling and more.
Pivot Park Screening Centre (PPSC) provides drug discovery services in the field of assay development, lab automation, (ultra) High Throughput Screening ((u)HTS)) and hit-2-lead testing to find novel leads for drug development.

The enzyme Arginase-1 has a regulatory role in T cell and natural killer cell-mediated immunity in the tumor microenvironment by decreasing levels of the amino acid L-arginine, which is critical for an effective anti-tumor immune response. Preclinical studies have shown that inhibition of Arginase-1 increases tumor immune cell infiltration and decreases tumor growth in model systems for cancer. The first small molecule Arginase-1 inhibitor CB-1158 (INCB001158) is currently being investigated in clinical trials for the treatment of advanced and metastatic tumors as a single agent, and in combination with chemotherapy, immune checkpoint therapy and the IDO1 inhibitor epacadostat.

The full article with references can be read on the website of NTRC